Recruiting Gout Studies in Chicago
A Study of Dotinurad Versus Allopurinol in Participants With Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated ...
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout....
About Gout Clinical Trials in Chicago
Gout is a form of inflammatory arthritis caused by elevated levels of uric acid in the blood, leading to crystal deposits in joints. It causes sudden, severe episodes of pain, swelling, and redness. Treatment includes anti-inflammatory medications for flares and urate-lowering therapy for prevention.
There are currently 2 gout clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 750 participants. Research is being sponsored by Crystalys Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Gout Clinical Trials in Chicago — FAQ
Are there gout clinical trials in Chicago?
Yes, there are 2 gout clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chicago?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.
Are clinical trials in Chicago free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.
What gout treatments are being tested?
The 2 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for gout.
Data updated March 2, 2026 from ClinicalTrials.gov